Showing 2761-2770 of 5646 results for "".
- Ocular Therapeutix Announces Receipt of C-Code and Pass-Through Payment Status for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-receipt-of-c-code-and-pass-through-payment-status-for-dextenza/2476614/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has approved transitional pass-through payment status and established a new reimbursement code for Dextenza (dexamethasone ophthalmic insert). The code, C9048, is scheduled to become effective July 1, 2019.
- NTC Grants Further License and Distribution Rights to Santen for Its Fixed Combination Dexamethasone With Levofloxacinhttps://modernod.com/news/ntc-grants-further-license-and-distribution-rights-to-santen-for-its-fixed-combination-dexamethasone-with-levofloxacin-in-south-east-asia/2476602/Italy-based NTC Srl and Santen Pharmaceutical announced an extension of their original agreement for Europe granting NTC’s license and distribution rights of levofloxacin+dexamethasone fixed combination eye drops to Santen. The countries covered by the exten
- Study Probes ODs’ Attitudes About Blue-Light Blocking Deviceshttps://modernod.com/news/study-probes-ods-attitudes-about-blue-light-blocking-devices/2476599/A recent study found that optometrists remain split on the impact of blue light from electronic devices, such as computer and phone screens, and the effectiveness of blue light-blocking devices, according to reporting by Patrick Campbell in MD Magazine, as
- Dexamethasone Injection May Speed IOP Drop in Angle-Closure Glaucomahttps://modernod.com/news/dexamethasone-injection-may-speed-iop-drop-in-angle-closure-glaucoma/2476594/In acute primary angle closure (APAC), subconjunctival dexamethasone injection helps high IOP drop more quickly and improves treatment success rate, researchers in China report, according to a Reuters report. “The anti-inflam
- Prevent Blindness Issues Call for Nominations for the 2019 Bonnie Strickland Champion for Children’s Vision Awardhttps://modernod.com/news/prevent-blindness-issues-call-for-nominations-for-the-2019-bonnie-strickland-champion-for-childrens-vision-award/2476590/The National Center for Children’s Vision and Eye Health at Prevent Blindness (NCCVEH) has issued the call for nominations for the fifth annual Bonnie Strickland Champion for Children’s Vision Award. The award recognizes significant efforts by an individual or group of individuals to improve publ
- Second Sight to Accelerate Development of Orion Visual Cortical Prosthesis Systemhttps://modernod.com/news/second-sight-to-accelerate-development-of-orion-visual-cortical-prosthesis-system/2476589/Second Sight Medical Products announced its plan to accelerate the development and commercialization of its Orion Visual Cortical Prosthesis System. Orion holds the potential to provide useful artificial vision to individuals blind from many causes, including glaucoma, eye injury, diabetic retino
- Colorlite Colorblind Diagnostic and Correction System Now Available in the United Stateshttps://modernod.com/news/colorlite-colorblind-diagnostic-and-correction-system-now-available-in-the-united-states/2476585/The Colorlite Colorblind Diagnostic and Correction System, which has been used in Europe for more than 20 years, is now available in the United States, according to a company news release. </
- Zeiss Opens Cinema Lens Demo Center in Los Angeleshttps://modernod.com/news/zeiss-opens-cinema-lens-demo-center-in-los-angeles/2476584/For over 100 years, Zeiss has provided cinematography lenses to filmmakers at all levels. From their headquarters in Germany, each cine lens is designed and manufactured at the highest quality and exhibits the versatile look with neutral color rendition Zeiss is k
- MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiencyhttps://modernod.com/news/meiragtx-announces-positive-6-month-data-from-phase-1-2-trial-of-investigational-gene-therapy-aav-rpe65-for-rpe65-deficiency/2476582/MeiraGTx Holdings announced positive data from a phase 1/2 dose escalation trial of AAV-RPE65, the company’s investigational gene therapy for the treatment of RPE65-deficiency, a condition that causes blindness. AAV-RPE65 is a second-generation gene therapy candidate developed specifically to tre
- Tilak Healthcare Announces Exclusive Partnership for Co-Promotion with Novartis Francehttps://modernod.com/news/tilak-healthcare-announces-exclusive-partnership-for-co-promotion-with-novartis-france/2476578/Tilak Healthcare, a video game studio specializing in mobile medical games for patients with chronic diseases, announced an exclusive co-promotion partnership with Novartis France for OdySight, its first clinically validated mobile game to monitor vision remotely. Tilak He